ARDX Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals has a net margin of -55.52% compared to Ardelyx's net margin of -55.29%. Ardelyx's return on equity of -34.68% beat Apellis Pharmaceuticals's return on equity of -96.34%.

Ardelyx has a consensus price target of $10.91, signalling upside risk potential of 137.15%. On the other hand Apellis Pharmaceuticals has an analysts' consensus of $35.45 which suggests that it could grow by 79.49%. Given that Ardelyx has higher upside potential than Apellis Pharmaceuticals, analysts believe Ardelyx is more attractive than Apellis Pharmaceuticals.

Ardelyx has a beta of 0.605, which suggesting that the stock is 39.538% less volatile than S&P 500. In comparison Apellis Pharmaceuticals has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.72%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Apellis Pharmaceuticals pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than Apellis Pharmaceuticals quarterly revenues of $166.8M. Ardelyx's net income of -$41.1M is higher than Apellis Pharmaceuticals's net income of -$92.2M. Notably, Ardelyx's price-to-earnings ratio is -- while Apellis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.01x versus 3.17x for Apellis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -55.52% compared to Ardelyx's net margin of 0.33%. Ardelyx's return on equity of -34.68% beat Blueprint Medicines's return on equity of -49.13%.

Ardelyx has a consensus price target of $10.91, signalling upside risk potential of 137.15%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.87%. Given that Ardelyx has higher upside potential than Blueprint Medicines, analysts believe Ardelyx is more attractive than Blueprint Medicines.

Ardelyx has a beta of 0.605, which suggesting that the stock is 39.538% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Ardelyx's net income of -$41.1M is lower than Blueprint Medicines's net income of $496K. Notably, Ardelyx's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.01x versus 14.74x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of -55.52% compared to Ardelyx's net margin of -74.86%. Ardelyx's return on equity of -34.68% beat AVITA Medical's return on equity of -415.55%.

Ardelyx has a consensus price target of $10.91, signalling upside risk potential of 137.15%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 217.12%. Given that AVITA Medical has higher upside potential than Ardelyx, analysts believe AVITA Medical is more attractive than Ardelyx.

Ardelyx has a beta of 0.605, which suggesting that the stock is 39.538% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than AVITA Medical quarterly revenues of $18.5M. Ardelyx's net income of -$41.1M is lower than AVITA Medical's net income of -$13.9M. Notably, Ardelyx's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.01x versus 1.94x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -55.52% compared to Ardelyx's net margin of 4.19%. Ardelyx's return on equity of -34.68% beat TG Therapeutics's return on equity of 19.78%.

Ardelyx has a consensus price target of $10.91, signalling upside risk potential of 137.15%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Ardelyx has higher upside potential than TG Therapeutics, analysts believe Ardelyx is more attractive than TG Therapeutics.

Ardelyx has a beta of 0.605, which suggesting that the stock is 39.538% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ardelyx's net income of -$41.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Ardelyx's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.01x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.